- Keywords
- orgánově specifická výživa, kyseliny mastné omega-3 (100 mg/ 1kg t.hm./den),
- MeSH
- Amino Acids * physiology metabolism MeSH
- Arginine * administration & dosage pharmacology therapeutic use MeSH
- Enteral Nutrition * MeSH
- Amino Acids, Essential * physiology metabolism therapeutic use MeSH
- Pharmacology * MeSH
- Glutamine * administration & dosage pharmacology therapeutic use MeSH
- Fatty Acids, Omega-6 * administration & dosage pharmacology therapeutic use MeSH
- Humans MeSH
- Nutritive Value * MeSH
- Nutrition Therapy * classification methods mortality standards nursing trends utilization MeSH
- Fatty Acids, Omega-3 * administration & dosage pharmacology therapeutic use MeSH
- Parenteral Nutrition * MeSH
- Food, Formulated * classification standards utilization MeSH
- Prospective Studies * MeSH
- Serine * administration & dosage pharmacology therapeutic use MeSH
- Taurine * administration & dosage pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
Látky, které modulují glutamátergní neurotransmisi, jsou již klinicky užívány v terapii Alzheimerovy choroby a v terapii některých afektivních poruch. Dysfunkce glutamátergní neurotransmise se může podílet také na patogenezi schizofrenie. V klinických studiích byly prokázány pozitivní terapeutické účinky látek agonisticky působích na glycinovém modulačním místě NMDA glutamátergních receptorů na schizofrenní symptomatiku. V poslední době je klinicky testován účinek látek regulujících extracelulární hladiny agonistů NMDA receptorů a látek ovlivňujících funkci AMPA receptorů. Východiskem hypotézy glutamátergní hyperfunkce je ovlivnění schizofrenní symptomatiky látkami snižujícími vyplavování glutamátu. Pozitivní účinek lamotriginu byl v adjuvantní terapii prokázán u pacientů se schizofrenií léčených atypickými antipsychotiky.
Glutamatergic neurotransmission modulators have been already used in the treatment of Alzheimer's disease and some affective disorders. Dysfunction of glutamatergic neurotransmission may be also involved in pathophysiology of schizophrenia. There is evidence of positive therapeutic effects of agonists of glycine modulátory site of NMDA receptors on symptoms of schizophrenia in clinical trials. The drugs modulating extracellular levels of NMDA receptor agonists and AMPA receptor modulators are currently under clinical evaluation. The hypothesis of glutamatergic hyperfunction proposed the effect of glutamate release-inibiting drugs in schizophrenia. Positive therapeutic effect of lamotrigine in add-on therapy has been demonstrated in patiens with schizophrenia treated with atypical antipsychotics.
- MeSH
- Anticonvulsants administration & dosage pharmacology chemistry MeSH
- Antipsychotic Agents administration & dosage pharmacology chemistry MeSH
- Cycloserine agonists administration & dosage pharmacology MeSH
- Research Support as Topic MeSH
- Receptors, Glutamate physiology MeSH
- Glutamates physiology metabolism MeSH
- Glycine agonists administration & dosage pharmacology MeSH
- Humans MeSH
- Neurotransmitter Agents antagonists & inhibitors pharmacology physiology MeSH
- Schizophrenia drug therapy physiopathology MeSH
- Serine agonists administration & dosage pharmacology MeSH
- Check Tag
- Humans MeSH
- MeSH
- Acute Disease therapy MeSH
- Drug Therapy methods utilization MeSH
- Research Support as Topic MeSH
- Data Interpretation, Statistical MeSH
- Humans MeSH
- Receptors, N-Methyl-D-Aspartate MeSH
- Recurrence MeSH
- Risperidone administration & dosage adverse effects therapeutic use MeSH
- Sarcosine administration & dosage adverse effects therapeutic use MeSH
- Schizophrenia drug therapy MeSH
- Serine administration & dosage adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Comparative Study MeSH
- MeSH
- Adrenalectomy * methods utilization MeSH
- Alanine administration & dosage drug effects MeSH
- Amino Acids * classification metabolism MeSH
- Biomedical Research MeSH
- Animal Experimentation MeSH
- gamma-Aminobutyric Acid administration & dosage drug effects MeSH
- Glucocorticoids administration & dosage MeSH
- Glutamine administration & dosage drug effects MeSH
- Glycine administration & dosage drug effects MeSH
- Cortisone administration & dosage MeSH
- Aspartic Acid administration & dosage drug effects MeSH
- Glutamic Acid drug effects MeSH
- Mineralocorticoids administration & dosage MeSH
- Brain * anatomy & histology enzymology drug effects MeSH
- Chromatography, Paper methods instrumentation utilization MeSH
- Rats, Wistar MeSH
- Serine administration & dosage drug effects MeSH
- Statistics as Topic MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
